HK Stock Market Move | Maiwei Biology-B (02493) rises by over 7% again, the world's first clearance-type antibody approved for clinical use in treating inflammatory bowel disease.

Meiweibi-B (02493) rose over 7% again, rising by 5.71% to 25.9 Hong Kong dollars with a trading volume of 48.537 million Hong Kong dollars as of the time of this report. On the news front, on June 4th, Meiweibi announced that its independently developed antibody innovative drug 9MW5211 injection has officially obtained approval from the National Medical Products Administration (NMPA) of China and can conduct clinical trials for inflammatory bowel disease (IBD). Previously, 9MW5211 had received FDA approval to conduct clinical trials for IBD in the United States. China Securities Co., Ltd. previously released a research report stating that upcoming events to watch for the company include: ST2 monoclonal antibody phase IIb clinical trial in the enrollment stage, with the potential to read out efficacy data in the future; Nectin-4ADC UC monotherapy, UC combination therapy, and CC monotherapy phase III clinical trials progressing, with an expected completion of mid-term analysis in 2026; LILRB4/CD3 TCE conducting a dual submission in the first half of 2026 for China and the United States, with multiple targeted solid tumor TCE projects expected to enter preclinical stages in the future; and potential business development.